於2024年8月9日，董事會及╱或董事會薪酬委員會根據2016期權及激勵計劃的 條款向五名承授人授出可認購合共22,835股美國存託股份的購股權。 授出購股權詳情 購股權詳情如下： | | | 相關股份數目： 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeiGene, Ltd. 百濟神州有限公司 （於開曼群島註冊成立的有限公司） （股份代號：06160） 授出購股權、受限制股份單位及業績股份單位 本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。於2024年8月9日， 董事會及╱或董事會薪酬委員會根據2016期權及激勵計劃的條款向五名承授人 授出可認購合共22,835股美國存託股份的購股權，向三百三十二名承授人授出涉 及合共87,399股美國存託股份的受限制股份單位，並向一名承授人授出涉及合共 9,119股美國存託股份的業績股份單位。 2016期權及激勵計劃項下的購股權 1 授出日期： 2024年8月9日 承授人數目： 五名 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 百濟神州有限公司（「本公司」）謹此公佈，本公司董事會（「董事會」）審計委員會 的會議將於2024年8月26日（美國東部時間）舉行，以（其中包括）審議及批准本公 司及其附屬公司截至2024年6月30日止六個月中期業績及根據香港聯合交易所有 限公司證券上市規則（「香港上市規則」）刊發中期業績。本公司先前於2024年8月 7日公佈其截至2024年6月30日止三個月及六個月的中期業績，並以提交表格10-Q 的方式將其季度業績送交美國證券交易委員會（「美國證券交易委員會」）存案。本 公司根據香港上市規則刊發的中期業績與本公司先前已公佈並送交美國證券交易 委員會存案者相同，惟根據香港上市規則所要求的指定附加資料及將本公司的中 期業績從美國公認會計原則與國際財務報表準則進行核對的結果除外。 於本公告日期，本公司董事會包括主席兼執行董事歐雷強先生、非執行董事王 曉東博士，以及獨立非執行董事Olivier Brandico ...

Group 1: Stock Performance and Price Targets - Shares of BeiGene, Ltd. (BGNE) have increased by 20.1% over the past four weeks, closing at $182.76, with a mean price target of $257.41 indicating a potential upside of 40.9% [1] - The mean estimate consists of 11 short-term price targets with a standard deviation of $56.75, suggesting variability in analyst predictions; the lowest estimate is $161 (11.9% decline), while the highest is $345 (88.8% increase) [1] Group 2: Analyst Sentiment and Earnings Estimates - There is strong agreement among analysts regarding BeiGene's ability to report better earnings, with five estimates revised higher in the last 30 days and no negative revisions, leading to a 39.2% increase in the Zacks Consensus Estimate [5] - The company currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [6] Group 3: Price Target Reliability - Analysts' price targets can often mislead investors, as empirical research indicates that they rarely predict actual stock price movements accurately [3] - A low standard deviation in price targets indicates a high degree of agreement among analysts, which can serve as a starting point for further research into fundamental drivers [4]

Investment Rating - The report maintains a "Buy" rating for both A-shares and H-shares of the company, with a target price of 180.24 CNY per share for A-shares and 200.27 HKD per share for H-shares [4]. Core Insights - The company reported a strong revenue growth of 65.4% year-on-year for the first half of 2024, reaching 11.996 billion CNY, while narrowing its net loss to 2.877 billion CNY [1]. - The core product, Baiyueze, saw global sales of 8.018 billion CNY in H1 2024, a significant increase of 122% year-on-year, with U.S. sales alone growing by 134.4% [1]. - The company has a rich pipeline of new drugs, with multiple candidates advancing through clinical trials, including Sonrotoclax and BGB-16673, which are in various stages of global registration [1]. Financial Summary - Revenue projections for the company are estimated at 25.177 billion CNY for 2024, 31.421 billion CNY for 2025, and 37.123 billion CNY for 2026, reflecting growth rates of 44.5%, 24.8%, and 18.1% respectively [2][3]. - The adjusted operating profit for Q2 2024 was reported at 345 million CNY, indicating improved operational efficiency driven by sales growth and cost management [1]. - The company is expected to continue narrowing its net losses, with projections of -2.876 billion CNY for 2024 and a potential return to profitability with a net profit of 1.759 billion CNY by 2026 [3].

证券研究报告·公司点评报告·生物制品 百济神州-U（688235） 2024 年 H1 业绩快报点评：核心产品放量超 预期，进入全球增长新阶段 2024 年 08 月 09 日 买入（维持） | --- | --- | --- | --- | --- | --- | |----------------------------|---------|--------|--------|--------|--------| | 盈利预测与估值 [Table_EPS] | 2022A | 2023A | 2024E | 2025E | 2026E | | 营业总收入（百万元） | 9,566 | 17,423 | 25,530 | 34,062 | 42,383 | | 同比（%） | 26% | 82% | 47% | 33% | 24% | | 归母净利润（百万元） | -13,642 | -6,716 | -3,116 | 274 | 636 | | 同比（%） | -40% | 51% | 54% | 109% | 132% | | EPS-最新摊薄（元/股） | -9.91 | -4.88 | -2.26 ...

美股代码：BGNE A 股代码：688235 A 股简称：百济神州 港股代码：06160 港股简称：百济神州 百济神州有限公司 投资者关系活动记录表 （2024 年 8 月） 投资者关系 √特定对象调研 □分析师会议 □媒体采访 □业绩说明会 活动类别 □新闻发布会 √路演活动 □现场参观 □一对一沟通 √其他（电话会议） 参与单位 3w 、 Ariose Capital 、 Balyasny Asset Management 、 Boyu 及人员 Captial 、 Capital Group 、 CSOP Asset Management 、 CTI Capital 、 Franklin Templeton Investments 、 Guotai Junan Assets Asia、HSBC GAM、IDG Capital、Invesco、Janchor Partners、Marshall Wace、New Silk Road、Point 72、SPDBI、Tiger Pacific Capital、安信基 金、奥昇投资、彼得明奇资管、财通资管、淳厚基金、大家资产、丹羿 投资、淡马锡、淡水泉投资、道翼资 ...

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of HKD 156.00, indicating a potential upside of 42.9% from the current price of HKD 109.20 [7]. Core Insights - The company has turned profitable in Q2 2024, reporting an adjusted non-GAAP operating profit of USD 48 million, a significant improvement from a loss of USD 193 million in Q2 2023. The operating cash outflow has narrowed to USD 404 million [1]. - The strong performance is attributed to the rapid growth in global sales of the drug Zebrutinib, which increased by 107% year-on-year and 30% quarter-on-quarter to USD 637 million, with U.S. sales growing by 114% year-on-year [1]. - The report projects an increase in the peak global sales forecast for Zebrutinib from USD 4.4 billion to USD 5.2 billion [1]. Financial Projections - Revenue projections for 2024-2026 have been raised by 13-18%, reflecting a more optimistic outlook on Zebrutinib sales and adjustments in gross margin and operating expense forecasts [2]. - The expected revenues are USD 3.463 billion for 2024, USD 4.366 billion for 2025, and USD 5.252 billion for 2026, with corresponding year-on-year growth rates of 40.8%, 26.1%, and 20.3% respectively [3][8]. - The company is expected to achieve a net profit of USD 410 million by 2026, compared to a projected loss of USD 762 million in 2024 [3][8]. Key Financial Metrics - The gross profit margin is expected to improve to 86.0% by 2026, up from 84.1% in 2024 [8]. - The report indicates a significant reduction in operating expenses, with R&D and SG&A expense ratios decreasing to 49% and 48% respectively by 2024 [1]. - The company’s cash flow situation is projected to improve, with free cash flow expected to turn positive by 2025 [6].

医药生物 2024 年 08 月 08 日 百济神州 (688235) ——泽布替尼高速增长，二季度非 GAAP 经营利润盈利 | --- | |---------------------| | 2024 年 08 月 07 日 | | 137.50 | | 163.88/98.50 | | 7.8 | | - | | 15,820 | | 2,869.83/8,449.58 | | | | --- | --- | |--------------------------|---------------------| | 基础数据: | 2024 年 03 月 31 日 | | 每股净资产（元） | 17.76 | | 资产负债率% | 40.51 | | 总股本/流通 A 股（百万） | 1,376/115 | | 流通 B 股/H 股（百万） | -/1,261 | 一年内股价与大盘对比走势： 08-0709-0710-0711-0712-0701-0702-0703-0704-0705-0706-0707-0708-07 -40% -20% 0% 20% 40% 60% 百济神州 沪深300指数 (收益率 ...

Investment Rating - The report maintains a "Buy" rating for the company and raises the target price to USD 285, HKD 171, and CNY 181 [1][3]. Core Insights - The company's Q2 2024 performance significantly exceeded expectations, primarily driven by strong sales growth of Zebutinib in the US and Europe. The company achieved its first adjusted Non-GAAP operating profit, marking a positive surprise in this earnings report [1]. - Total revenue for Q2 2024 reached USD 929 million, representing a year-over-year increase of 56.1% and a quarter-over-quarter increase of 23.6%. Product revenue was USD 921 million, up 66.3% year-over-year and 23.2% quarter-over-quarter, significantly surpassing expectations [1]. - Zebutinib's global sales reached USD 637 million, with US sales at USD 479 million, reflecting a year-over-year increase of 114.4% and a quarter-over-quarter increase of 36.3%. The management indicated that Zebutinib has captured over 40% market share in the CLL indication in the US [1][3]. Summary by Sections Financial Performance - The company reported a net loss of USD 120 million for Q2 2024, a decrease of 68.4% year-over-year and 52.1% quarter-over-quarter, which was better than expectations due to stronger product revenue and higher gross margins [1]. - The overall product gross margin reached 85% in Q2 2024, up 2.3 percentage points year-over-year and 1.7 percentage points quarter-over-quarter [1]. Research and Development Progress - The company is focusing on key pipeline projects, including Sonrotoclax (BCL2) and BGB-16673 (BTK CDAC), with ongoing clinical trials and expected data readouts in late 2024 and early 2025 [1][3]. - The management anticipates further improvements in gross margins and a reduction in R&D and administrative expense ratios as Zebutinib sales continue to grow [1]. Market Position and Strategy - The company announced a relocation of its registered office from the Cayman Islands to Switzerland, reflecting its global strategic expansion [3]. - The establishment of a large-scale production facility in New Jersey is now operational, which will support the supply of its products in the US and Europe [3].

Investment Rating - The report maintains a "Buy" rating for BeiGene, with a target price adjustment from $269.73 to $288.93 [2][18]. Core Insights - BeiGene's product sales exceeded expectations, recording $921 million in Q2 2024, representing a 23% quarter-over-quarter growth and a 66% year-over-year increase [1][2]. - The company achieved non-GAAP profitability, with a significant reduction in net loss to $120 million in Q2 2024 from $251 million in Q1 2024 [2][3]. - Strong sales momentum for Zanubrutinib (Zanu) was noted, with Q2 sales reaching $637 million, a 30% increase quarter-over-quarter and a 107% increase year-over-year [1][2]. Financial Performance - Total product sales for the first half of 2024 reached $1.67 billion, accounting for 51.4% of the previously estimated total for fiscal year 2024 [1][2]. - The gross profit margin increased to 85.0% in Q2 2024 from 83.3% in Q1 2024, driven by a higher proportion of high-margin sales [2][3]. - The SG&A ratio decreased to 48% in Q2 2024 from 57% in Q1 2024, indicating improved operational efficiency [2][3]. Market Position and Growth Potential - Zanu captured approximately 24% of the global BTK inhibitor market in Q2 2024, up from 20% in Q1 2024, with expectations to reach $2.6 billion in sales for FY24, a 102% year-over-year increase [2][3]. - The report highlights the potential of upcoming clinical trials for Sonrotoclax and BGB-16673, which are expected to drive future growth [2][3]. Future Projections - The company is projected to achieve breakeven in FY25E, supported by strong sales growth and improving operating margins [2][3]. - Revenue estimates for FY24E, FY25E, and FY26E are $3.87 billion, $5.49 billion, and $6.99 billion, respectively, with a focus on continued product sales growth [3][12].